nik-macmillan-280300.jpg

investors

 
 

STOCK INFORMATION

BlissCo is currently trading on the following stock exchanges:

Canadian Stock Exchange (CSE) as BlissCo Cannabis Corp. (BLIS)

Frankfurt Stock Exchange (FRA) as GQ4B:GR

 

BlissCo One Step Closer to Medical Cannabis Exports to Germany

  • Not for distribution in the U.S. or to U.S. newswire services.

Vancouver, British Columbia – July 26, 2018 – BlissCo Cannabis Corp. (FRA: GQ4B) (CSE: BLIS), (“BlissCo”) or the (“Company”)

is pleased to announce that it has completed a Good Manufacturing Practices (GMP) Gap Assessment.

This Gap Assessment brings BlissCo one step closer to earning its Eudralex GMP certification that will allow the company to export to European markets, including the German market, once the Company has  also earned its sales license. It is estimated that demand for medical marijuana in Germany could ultimately reach 126,000 kg per year.

“Currently there are eight Canadian ACMPR Licensed Producers with licensed facilities that are GMP certified through the Eudralex European regulatory body. Based on the positive feedback we received at the completion of our two day GMP Gap Assessment, we are confident that BlissCo will earn our European GMP certification in Q4 2018,” said BlissCo CEO Damian Kettlewell. “Once we earn our European GMP certification and an amendment to our ACMPR license to sell, which is under active review by Health Canada, our German distribution partner will be able to apply for an import certificate which will enable us to  export cannabis to fulfil the 720 kg supply agreement to Germany that we announced in June 2018,"

Germany is expected to rely on imports to meet 100% of the country’s medical cannabis demand until at least 2020.

“BlissCo has a state of the art ACMPR facility and our GMP Gap Assessment team was impressed with BlissCo’s cultivation and operational setup. We feel that their facility has the potential to be one of the first 12 GMP certified facilities in Canada,” says Deepak Anand, VP of Business Development for Cannabis Compliance Inc.

It is estimated that the international medical cannabis market could reach $100 billion in annual retail value in the next 5-10 years.

“Earning our European GMP certification and sales license amendment will enable BlissCo to service patients in Canada and medical distribution partners in Europe as we expand the BlissCo Ecosystem. Fulfilling agreements within the German market can also serve as a stepping stone to the rest of the European markets when and where medical cannabis is legal,” said BlissCo CEO Damian Kettlewell.

 

About BlissCo Cannabis Corp.

BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships.  

BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.

BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo's future patients and customers.

Learn more: BlissCo.com

 

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

 

For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations 

 1-604-377-7533

ariel.lewinski@blissco.com

 

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

See All Investor Updates

OUR COMPANY

As Canada is primed as a global leader and first mover in the cannabis industry, BlissCo is uniquely poised in the rapidly growing multi-billion dollar market and in various international markets as cannabis regulations progress.

BlissCo, founded in 2013, is a Canadian vertically integrated cultivation, extraction and distribution focused cannabis brand that earned its Access to Cannabis for Medical Purposes Regulations (ACMPR) license to cultivate from Health Canada on March 29, 2018.

BlissCo's state-of-the-art production facility, located in Metro Vancouver, is purposefully designed as a hub for research, cultivation, processing, extraction, packaging and distribution.

Now with the ACMPR license to cultivate, BlissCo will commence its operation to harvest premium cannabis within its' urban facility in Metro Vancouver.  BlissCo also has a multi-year supply agreement in place with a Canadian Licensed Producer of characteristically sun-grown premium medicinal cannabis to purchase supply in large volumes (news release). This premium bulk cannabis will be brought to our secure and pristine facility in British Columbia for processing and then be packaged for sale and distribution to our growing patient list when BlissCo has appropriately received its license for sale. 

BlissCo was founded with the assistance of a team of advisors, including medical and naturopathic doctors, has intentionally engaged with the medical community to understand how to contribute to improved patient health with medicinal cannabis products. A large part of our strategy for growth centres on how to securely integrate and collaborate with the healthcare system.

The BlissCo team has deep domain expertise in the critical category success areas:

  • Multi-province controlled substance distribution (BC and Alberta)
  • Cultivation and product safety, consistency and security
  • Indoor cultivation, controlled environments ensuring high standards &  consistent products.
  • Quality assurance, product safety, 3rd Party GMP Audits & Certifications.


Milestones

2018

February

Strategic partnership with the Supreme Cannabis Company

Trading on Canadian Securities Exchange (CSE:BLIS)

March
ACMPR License to Produce earned

May

Cannabis plant starting material to arrive at BlissCo's facility and growing commences. 

ACMPR Cannabis Oil Extraction License application submitted

June

Sign agreement to export 720 kilograms of medical cannabis to Germany

July

ACMPR License to Sell application submitted

Sign supply agreement with GreenSeal Cannabis

Sign e-commerce and technology service agreement with Namaste Technologies (TSXV: N) 

2017

February
Confirmation of Readiness for Inspection received from Health Canada

May
Confirmation of Readiness for License from Health Canada

August
Close on purchasing facility for $2.4m

September
Earn Building Permit from Township of Langley
Commence Construction

2014

July
ACMPR Licensed Submitted